Global Creutzfeldt-Jakob Disease (CJD) Market Size, Share, Forecast Report, 2020-2027

Creutzfeldt-Jakob disease or CJD is a rare, degenerative brain disorder which may lead to dementia and sudden death. The early stage symptoms of the disease include failing memory and lack of coordination followed by visual disturbances. As the disease progresses, mental deterioration becomes prominent leading to weakness of extremities, and conditions like coma. The CJD disease can be classified into three major groups, namely sporadic CJD, hereditary CJD, and acquired CJD. Sporadic CJD is the most common form of the disease and accounts for approximately 85% of the total reported cases. A majority of the treatments available in the market are symptomatic and aimed at alleviating pain. The risk factors for the development of the disease are inclusive of old age, familial CJD genetics, and others. Increasing prevalence of Creutzfeldt-Jakob disease and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. In 2017, the National Institute of Neurological Disorders and Stroke stated that approximately 300 new cases of CJD are reported every year within the U.S. Moreover, it has been estimated that the symptomatic onset of the medical condition occurs predominantly around the age of 60. Additionally, according to the United States Census Bureau, the global geriatric population is projected to more than double and reach 1.6 billion from 2025 to 2050. Additionally, factors such as increasing per capita healthcare expenditure and extensive research and development by the market players will drive the market growth. However, lack of awareness, limited availability of therapeutics, and erroneous diagnostic results are estimated to restrain the market growth during the forecast period.

The global Creutzfeldt-Jakob disease (CJD) market is expected to grow at an approximate CAGR of 17.5% during forecast period.
Segmentation

The global Creutzfeldt-Jakob disease (CJD) market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is segmented into sporadic CJD, hereditary CJD, and acquired CJD. On the basis of the diagnosis, the market is categorized into imaging, spinal fluid tests, brain biopsy, and others. The imaging segment is sub-segmented into electroencephalogram (EEG), magnetic resonance imaging (MRI), computerized tomography (CT), and others. On the basis of the treatment, the market is segmented into opiate drugs, clonazepam, sodium valproate, and others. On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, diagnostic centers, medical research institutes, and others.
Key players

Some of the key players for the global Creutzfeldt-Jakob disease (CJD) market are Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Sandoz International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Apotex Inc. (Canada), Par Pharmaceutical. (U.S.), GENERAL ELECTRIC (U.S.), Koninklijke Philips N.V. (The Netherlands), Medtronic (U.S.), Siemens AG (Germany), Accuray Incorporated (U.S.), and others.